Actemra®/RoActemra® | Tocilizumab | Roche
29 Apr 20 | All | Gedeon Richter, Mycenax | Gedeon Richter announces it has entered an asset purchase agreement with Mycenax Biotech for the purchase of a biosimilar tocilizumab product. Under the agreement, Richter will receive worldwide rights to develop, manufacture and commercialise the product which is expected to reach global markets in 2025.
27 Jan 19 | All | Bio-Thera | Bio-Thera announces commencement of Ph III trials of BAT1806, its proposed tocilizumab biosimilar. Results are expected in the second half of 2020.
24 Dec 18 | All | Mycenax | Mycenax announces positive results from Ph I PK clinical trials, reporting the product met the primary endpoint in PK comparison.